A careful approach towards ASK1 inhibitors is needed; however, as it has also been reported that liver-specific ASK1 overexpression ameliorated hepatic steatosis and liver fibrosis through the induction of autophagy in mice [68]. Here, MAP3K5 is linked to fatty liver disease.